Breast Cancer Clinical Trials in Massachusetts

Showing 141-160 of 511 trials

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

NCT03414684

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body. The interventions involved in this study are: * Carboplatin * Nivolumab

Breast Cancer

Dana-Farber Cancer Institute78 participantsStarted Jan 2018

Stamford, Connecticut, United States • Bangor, Maine, United States • Boston, Massachusetts, United States +7 more locations

Active Not RecruitingPhase 318 miles

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).

Triple Negative Breast CancerPD-L1 Positive

Gilead Sciences443 participantsStarted Jul 2022

Anchorage, Alaska, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +501 more locations

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Breast Cancer Trials in Other Cities

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

The COMPASSION Study

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

MarginProbe 2.0 Data Collection Protocol

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Other Conditions in Massachusetts